Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib and Dostarlimab in BRCA1/2 and PALB2-Mutated Pancreatic Cancer
NCT04493060Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Dec 2020
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib, dostarlimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Mayo Clinic. Started Dec 2020; status: completed.
02
Drugs
niraparibdostarlimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04493060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04493060.